Unicycive Therapeutics Announced Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC)

Source :: Plus Company Updates. July 12, 2024
Publication Year :: 2024
Abstract: LOS ALTOS: Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the Company or Unicycive), today announced the initial results from the patient [...]

Subjects :: Medical research -- Surveys
Medicine, Experimental -- Surveys
Chronic kidney failure -- Surveys
Patient satisfaction -- Surveys
Carbonates -- Product development
Clinical trials -- Surveys
General interest
News, opinion and commentary

Tools